📊 AUTL Key Takeaways
Investment Thesis
Autolus is a pre-commercial or early-stage biopharmaceutical company with minimal revenue relative to operating expenses, resulting in severe operating losses and negative free cash flow of -$236.2M. While strong liquidity metrics (6.19x current ratio) provide a near-term runway, the company is burning cash at an unsustainable rate and faces fundamental questions about commercialization success and path to profitability.
AUTL Strengths
- Strong liquidity position with $86.1M cash and 6.19x current ratio providing operational runway
- Dramatic revenue growth of +496% YoY indicating successful product commercialization or launch
- Zero long-term debt and low leverage (0.00x debt-to-equity) reduces financial distress risk
AUTL Risks
- Severe cash burn of -$216.2M operating cash flow with negative free cash flow of -$236.2M indicating unsustainable burn rate
- Operating margins of -387.6% and net margins of -385.9% show company is losing $3.86 for every dollar of revenue generated
- EPS of -$0.74 and ROE of -74.3% demonstrate significant losses; current cash runway of approximately 0.4 years at current burn rate
- Early-stage biotech with no gross profit visibility, suggesting revenue insufficient to cover cost of goods sold
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue growth sustainability and gross margin expansion as commercialization scales
- Operating cash flow trend and pathway to cash flow breakeven
- Funding activities and capital raise requirements
AUTL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.19x current ratio provides a solid financial cushion.
AUTL Profitability Ratios
AUTL vs Healthcare Sector
How Autolus Therapeutics plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AUTL Balance Sheet & Liquidity
AUTL 5-Year Financial Trend
5-Year Trend Summary: Autolus Therapeutics plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.20 indicates the company is currently unprofitable.
AUTL Growth Metrics (YoY)
AUTL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$79.1M | $-0.30 |
| Q2 2025 | N/A | -$47.9M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AUTL Capital Allocation
AUTL SEC Filings
Access official SEC EDGAR filings for Autolus Therapeutics plc (CIK: 0001730463)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AUTL
What is the AI rating for AUTL?
Autolus Therapeutics plc (AUTL) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AUTL's key strengths?
Strong liquidity position with $86.1M cash and 6.19x current ratio providing operational runway. Dramatic revenue growth of +496% YoY indicating successful product commercialization or launch.
What are the risks of investing in AUTL?
Severe cash burn of -$216.2M operating cash flow with negative free cash flow of -$236.2M indicating unsustainable burn rate. Operating margins of -387.6% and net margins of -385.9% show company is losing $3.86 for every dollar of revenue generated.
What is AUTL's revenue and growth?
Autolus Therapeutics plc reported revenue of $51.1M.
Does AUTL pay dividends?
Autolus Therapeutics plc does not currently pay dividends.
Where can I find AUTL SEC filings?
Official SEC filings for Autolus Therapeutics plc (CIK: 0001730463) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AUTL's EPS?
Autolus Therapeutics plc has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.